Terbinafine;Terbinafine

Annales de Dermatologie et de Venereologie

Volumn 126, Issue 1, 1999, Pages 81-89

  Bouyssou Gauthier, M L ^a   Bonnetblanc, J M ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CICLOPIROXOLAMINE; FLUCYTOSINE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; OXICONAZOLE; TERBINAFINE;

ANTIFUNGAL ACTIVITY; ARTICLE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; ORAL DRUG ADMINISTRATION;

ANTIFUNGAL AGENTS; CLINICAL TRIALS; DERMATOMYCOSES; HUMANS; NAPHTHALENES;

EID: 0033021323     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Balfour JA, Faulds D. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992;43:259-84.
2. Georgopapadakou NH, Walsh TJ. Human Mycoses: Drugs and targets for emerging pathogens. Science 1994;264:371-3.
3. Gupta AK, Shear NH. Terbinafine: an update. J Am Acad Dermatol 1997;37:979-88.
4. Villars V, Jones TC. Present status of the efficacy and tolerability of terbinafine (Lamisil®) used systemically in the treatment of dermatomycoses of skin and nails. J Dermatol Treat 1990;1(Suppl 2):33-8.
5. Samsoen M. La terbinafine (Lamisil®): la première allylamine fongistatique et fongicide per os. Nouv Dermatol 1992;11:743-62.
6. Terbinafine. Rev Contemporary Pharmacother 1997;8:275-396.
7. Embase CD: Dermatology, Elsevier Science BV, Silver Platter International NV, 1986-September1997.
8. Physicians' SilverPlatter: Dermatology CD-ROM American Academy of Dermatology, Silver Platter International NV, 1966-August1997.
9. Ryder NS, Favre B. Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmacother 1997;8:275-87.
10. Elewski BE. Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol 1993;28:S28-S34.
11. Shadomy S, Espinel-Ingroff A, Gebhart RG. In vitro studies with SF-327, a new orally active allylamine derivative. J Med Veter Mycol 1985;23: 123-32.
12. Jensen JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol 1989;14: 110-3.
13. Stephen A, Czok R, Male O. Terbinafine: initial clinical results. In Fromtling RA (Ed.) Recent trends in discovery, development and evaluation of antifungal agents, JR Prous Science Publishers S.A. Barcelona, 1987;511-20.
14. Lever LR, Dykes PJ, Thomas R, Finlay AY. How orally administered terbinafine reaches the stratum corneum. J Dermatol Treat 1990; 1(Suppl. 2):23-5.
15. Hill S, Thomas R, Smith SG, Finlay AY. An investigation of pharmacokintics of topical terbinafine (Lamisil®) 1 p. 100 cream. Br J Dermatol 1992;127:396-400.
16. Goodfield MJD, Andrew L, Evans EGV. Short term treatment of dermatophyte onychomycosis with terbinafine. Br Med J 1992;304:1151-3.
17. Watson A, Marley J, Ellis D, Williams T. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol 1995;33:775-9.
18. De Cuyper C. Long-term evaluation of terbinafine 250 and 500 mg daily in a 16-week oral treatment for toenail onychomycosis. Br J Dermatol 1996;135:156-7.
19. Hofmann H, Bräutigam M, Weidinger G, Zaun H, and the LAGOS Study group. Treatment of toenail onychomycosis. A randomized double-blind study with terbinafine and griseofulvin. Arch Dermatol 1995;131:919-22.
20. Baran R, Belaich S, Beylot C, Bonnetblanc JM, Cribier B, Daniel F et al. Comparative multicentre double-blind study of terbinafine (250 mg per day) versus griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis. J Dermatol Treat 1997;8:93-7.
21. Bräutigam M, Nolting S, Schöpf RE, Weidinger G for the Seventh Lamisil® German Onychomycosis Study Group. German randomized double-blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. Br J Dermatol 1996;134(S 46):18-21.
22. De Backer M, De Keyser P, De Vroey C, Lesaffre E. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs itraconazole 200 mg/day: a double blind comparative trial. Br J Dermatol 1996; 134(S46):16-7.
23. Tosti A, Piraccini BM, Stinchi C, Venturon N, Bardazzi F, Colombo MD. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996;34:595-600.
24. Nolting S, Bräutigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophyte fungi. Br J Dermatol 1994; 130(S43):16-21.
25. Ellis DH, Marley JE, Watson AB, Williams TG. Significance of non-dermatophyte moulds ans yeasts in onychomycosis. Dermatology 1997;194(S1):S40-2.
26. Berman B, Ellis C, Leydon J, Lowe N, Savin R, Shupack J et al. Efficacy of a 1-week, twice daily regimen of terbinafine 1 p. 100 cream in the treatment of interdigital tinea pedis: results of placebo-controlled, double-blind multicenter trials. J Am Acad Dermatol 1992;26:956-60.
27. Savin R, Atton AV, Bergstresser PR, Elewski B, Earl Jones H, Levine N et al. Efficacy of terbinafine 1 p. 100 cream in the treatment of moccasin-type tinea pedis: results of placebo-controlled multicenter trials. J Am Acad Dermatol 1994;30:663-7.
28. Evans EGV. The clinical efficacy of terbinafine in the treatment of fungal infections ofthe skin. Rev Contemp Pharmacol 1997;8:325-41.
29. Elewski B, Bergstresser PR, Hanifin G, Lesher J, Savin R, Shupack J et al. Long-term outcome of patients with interdigital tinea pedis treated with terbinafine and clotrimazole. J Am Acad Dermatol 1995;32:290-2.
30. White JE, Perkins PJ, Evans EGV. Successful 2-week treatment with terbinafine (Lamisil®) for moccasin tinea pedis and tinea manuum. Br J Dermatol 1991;125:260-2.
31. Hay RJ, Logan RA, Moore MK, Midgely G, Clayton YM. A comparative study of terbinafine versus griseofulvin in "dry-type" dermatophyte infections. J Am Acad Dermatol 1991;24:243-6.
32. Evans EGV, Shah JM, Joshipura RC. One-week treatment of tinea corporis and tinea cruris with terbinafine (Lamisil®) 1 p. 100 cream: a placebo controlled study. J Dermatol Treat 1992; 3:181-3.
33. Faergemann J, Hersle K, Nordin P. Pityriasis versicolor: clinical experience with Lamisil cream and Lamisil® Derm Gel. Dermatology 1997;194(Suppl 1):19-21.
34. Vermeer BJ, Staats CC. The efficacy of a topical application of terbinafine 1 p. 100 solution in subjects with pityriasis versicolor: a placebo-controled study. Dermatology 1997; 194(Suppl 1):22-4.
35. Jones TC. Overview of the use of terbinafine (Lamisil®) in children. Br J Dermatol 1995;132: 683-9.
36. Krafchik B. The clinical efficay of terbinafine in the treatment of tinea capitis. Rev Contemp Pharmacother 1997;8:313-24.
37. Bruckbauer HR, Hofmann H. Systemic antifungal treatment of children with terbinafine. Dermatology 1997;195:134-6.
38. Dragos V, Lunder M. Lack of efficacy of 6-week treatment with oral terbinafine for tinea capitis due to Microsporon canis in children. Pediatr Dermatol 1997;14:46-8.
39. Gupta AK, Sibbald RC, Lynde CW, Hull PR, Prussick R, Shear NH et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol 1997;36:395-402.
40. Bakos L, Brito AC, Castro LCM, Gontijo B, Lowy G, Reis CMS et al. Open clinical study of the efficacy and safety of terbinafine cream 1 p. 100 in children with tinea corporis and tinea cruris. Pediatr Infect Dis 1997;16:545-8.
41. Suhonen R, Naivonen PJ. The tolerability profile of terbinafine. Rev Contemp Pharmacother 1997;8:373-86.
42. Sayag J, Badillet G, Zagula M. Efficacité et tolérance du Lamisil (terbinafine). Etude multicentrique dans les mycoses cutanées et unguéales. Nouv Dermatol 1995;14-547-52.
43. Hall M, Monka C, Krupp P, O'Sullivan D. Safety of oral terbinafine. Results of a postmarketing surveillance study in 25 884 patients. Arch Dermatol 1997;133:1213-9.
44. Mallat A, Zafrani ES, Metreau JM, Dhumeaux D. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. Dig Dis Sci 1997;42:1486-8.
45. Gupta AK, Kopstein J, Shear NH. Hypersensitivity reaction to terbinafine. J Am Acad Dermatol 1997;36:1018-9.
46. Gupta AK, Sibbald RC, Knowles SR, Lynde CW, Shear NH. Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: Four case reports and a review of drug-induced psoriasis. J Am Acad Dermatol 1997;36:858-62.
47. Beutler M, Hartmann K, Kuhn M, Gartman J. Taste disorders and terbinafine (letter). Br Med J 1993;307:26.
48. Barete S, Bissuel F, Longuet P, Pocidalo MA, Leport C, Vilde JL. Agranulocytose au cours d'un traitement par terbinafine. Rev Med Interne 1997;18:258-9.
49. Jensen P, Lehne G, Fauchald P, Simonsen S. Effect of oral terbinafine treatment on cyclosporin pharmacokinetics in organ transplant recipients with dermatophyte nail infections. Acta Derm Venereol (Stockh) 1996;76:280-1.